2. Search Result
Search Result
Results for "

Dxd

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

6

Fluorescent Dye

1

Biochemical Assay Reagents

1

Inhibitory Antibodies

8

Isotope-Labeled Compounds

1

Antibodies

2

Click Chemistry

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13631E
    Deruxtecan
    Maximum Cited Publications
    25 Publications Verification

    MC-GGFG-Dxd

    		 Drug-Linker Conjugates for ADC Cancer
    Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
    Deruxtecan
  • HY-13631D
    DXd
    10+ Cited Publications

    Exatecan derivative for ADC

    		 Topoisomerase ADC Payload Cancer
    DXd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).
    DXd
  • HY-141598
    Datopotamab deruxtecan
    2 Publications Verification

    DS-1062; Dato-Dxd

    		 TROP2 Antibody-Drug Conjugates (ADCs) Topoisomerase Cancer
    Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan has a potent antitumor activity .
    Datopotamab deruxtecan
  • HY-138298
    Trastuzumab deruxtecan (solution)
    5 Publications Verification

    T-Dxd (solution); DS-8201 (solution); DS-8201a (solution)

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan (solution)
  • HY-138298A
    Trastuzumab deruxtecan
    5 Publications Verification

    T-Dxd; DS-8201; DS-8201a

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan
  • HY-P3371
    Ifinatamab deruxtecan

    DS-7300a; MABX-9001a; I-Dxd

    		 Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis Cancer
    Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
    Ifinatamab deruxtecan
  • HY-134723
    DBCO-PEG4-GGFG-Dxd
    1 Publications Verification

    		 Drug-Linker Conjugates for ADC Cancer
    DBCO-PEG4-GGFG-Dxd is a agent-linker conjugate for ADC with potent antitumor activity by using Dxd (a DNA topoisomerase I inhibitor), linked via the cleavable ADC linker DBCO-PEG4-GGFG . DBCO-PEG4-GGFG-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-GGFG-Dxd
  • HY-P99813
    Patritumab deruxtecan

    HER3-Dxd; U3-1402

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
    Patritumab deruxtecan
  • HY-13631DS
    DXd-d5

    Exatecan-d5 derivative for ADC

    		 Topoisomerase ADC Payload Cancer
    DXd-d5 is a deuterium labeled DXd. DXd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) .
    DXd-d5
  • HY-164734
    Raludotatug Deruxtecan

    R-Dxd; DS-6000

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Raludotatug Deruxtecan is an antibody-drug conjugate targeting CDH6, with an EC50 of 64.7 ng/mL in humans, 70.4 ng/mL in cynomolgus monkeys, and 228 ng/mL in mice. Raludotatug Deruxtecan specifically binds to CDH6 on the surface of cancer cells, triggers lysosomal internalization, and releases the DXd payload that inhibits TOP1. Raludotatug Deruxtecan induces DNA damage, Chk1 phosphorylation, caspase-3 cleavage, apoptosis, and bystander cell death. Raludotatug Deruxtecan is applicable to research related to serous ovarian cancer and renal cell carcinoma .
    Raludotatug Deruxtecan
  • HY-158768
    Amino-PEG4-GGFG-Dxd

    		Drug-Linker Conjugates for ADC Cancer
    Amino-PEG4-GGFG-Dxd (Compound 13-7) is a drug-linker conjugate for ADC. Amino-PEG4-GGFG-Dxd is composed of Dxd (HY-13631D) and a linker. Amino-PEG4-GGFG-Dxd can be used for synthesis of ADCs
    Amino-PEG4-GGFG-Dxd
  • HY-156755
    Propargyl-PEG4-GGFG-DXd

    		Drug-Linker Conjugates for ADC Cancer
    Propargyl-PEG4-GGFG-DXd is a drug-linker conjugate for ADC. Propargyl-PEG4-GGFG-DXd contains a ADC linker and a DNA topoisomerase I inhibitor DXd (HY-13631D) .
    Propargyl-PEG4-GGFG-DXd
  • HY-156848
    Fmoc-GGFG-DXd

    		Drug-Linker Conjugates for ADC Cancer
    Fmoc-GGFG-DXd is a drug-linker conjugate for ADC. Fmoc-GGFG-DXd contains a ADC linker Fmoc-GGFG and a DNA topoisomerase I inhibitor DXd (HY-13631D) .
    Fmoc-GGFG-DXd
  • HY-177442
    DS-3939a

    DS-3939

    		 Antibody-Drug Conjugates (ADCs) Mucin Topoisomerase Apoptosis Cancer
    DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .
    DS-3939a
  • HY-147363
    DIBAC-GGFG-NH2CH2-Dxd

    		Drug-Linker Conjugates for ADC Others
    DIBAC-GGFG-NH2CH2-Dxd (compound LP4), a Camptothecin (HY-16560) derivative, is a linker-payload of protein-agent conjugates . Dxd (HY-13631D) can be used as a payload for the antibody-coupling drug ADC (DS-8201a).DIBAC-GGFG-NH2CH2-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .
    DIBAC-GGFG-NH2CH2-Dxd
  • HY-13631EG
    Deruxtecan

    MC-GGFG-Dxd

    		 Drug-Linker Conjugates for ADC Cancer
    Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
    Deruxtecan
  • HY-13631ES4
    Deruxtecan-d5

    MC-GGFG-Dxd-d5

    		 Isotope-Labeled Compounds Drug-Linker Conjugates for ADC Cancer
    Deruxtecan-d5 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d5
  • HY-164729
    FZ-AD005

    		Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis Cancer
    FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The Kd value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .
    FZ-AD005
  • HY-176415
    Cys-MC-GGFG-Dxd

    		Drug-Linker Conjugates for ADC Cancer
    Cys-MC-GGFG-Dxd is a cysteine-modified, cleavable ADC drug-linker conjugate. Cys-MC-GGFG-Dxd consists of a maleimidocaproyl-glycine-glycine-L-phenylalanine-glycine (MC-GGFG) linker and an Exatecan (HY-13631) derivative (DXd) (HY-13631D) payload. Cys-MC-GGFG-Dxd can be further conjugated to anti-HER2 IgG1κ antibody for the synthesis of antibody-drug conjugates (ADC), such as the breast cancer-targeting ADC compound Fam-trastuzumab deruxtecan-nxki (Enhertu) .
    Cys-MC-GGFG-Dxd
  • HY-158137
    Val-Cit-PAB-DEA-Dxd

    		Drug-Linker Conjugates for ADC Cancer
    Val-Cit-PAB-DEA-Dxd (compound 81) is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Dxd (DNA topoisomerase I inhibitor). Val-Cit-PAB-DEA-Dxd can be used for ADC synthesis .
    Val-Cit-PAB-DEA-Dxd
  • HY-160098
    BCN-linker-DXd 2

    		Drug-Linker Conjugates for ADC Cancer
    BCN-linker-DXd 2 is an ADC linker. BCN-linker-DXd 2 can be used for the research of cancer .
    BCN-linker-DXd 2
  • HY-13631ES3
    Deruxtecan-d2

    MC-GGFG-Dxd-d2

    		 Drug-Linker Conjugates for ADC Isotope-Labeled Compounds Others
    Deruxtecan-d2 is the deuterium labeled Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d2
  • HY-13631ES
    Deruxtecan-d4

    MC-GGFG-Dxd-d4

    		 Drug-Linker Conjugates for ADC Isotope-Labeled Compounds Others
    Deruxtecan-d4 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d4
  • HY-178262A
    thioxo-Dxd

    		ADC Payload Cancer
    thioxo-Dxd is a Camptothecin (HY-16560) derivative. thioxo-Dxd can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. thioxo-Dxd can be used for research on tumors with high HER2 or TROP2 expression .
    thioxo-Dxd
  • HY-158137A
    Val-Cit-PAB-DEA-Dxd TFA

    		Drug-Linker Conjugates for ADC Cancer
    Val-Cit-PAB-DEA-Dxd (Compound 81) TFA is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Dxd (HY-13631D). Val-Cit-PAB-DEA-Dxd can be used for ADC synthesis .
    Val-Cit-PAB-DEA-Dxd TFA
  • HY-13631ES2
    Deruxtecan-d4-1

    MC-GGFG-Dxd-d4-1

    		 Drug-Linker Conjugates for ADC Isotope-Labeled Compounds Others
    Deruxtecan-d4-1 is the deuterium labeled Adenosine Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d4-1
  • HY-13631ES1
    Deruxtecan-d6

    MC-GGFG-Dxd-d6

    		 Drug-Linker Conjugates for ADC Others
    Deruxtecan-d6 is the deuterium labeled Deruxtecan .
    Deruxtecan-d6
  • HY-178262
    (R)-thioxo-Dxd

    		ADC Payload Cancer
    (R)-thioxo-Dxd is a Camptothecin (HY-16560) derivative. (R)-thioxo-Dxd can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. (R)-thioxo-Dxd can be used for research on tumors with high HER2 or TROP2 expression .
    (R)-thioxo-Dxd
  • HY-13631K
    (1R,9S)-Dxd

    		ADC Payload Cancer
    (1R,9S)-Dxd is an isomer of (Dxd) HY-13631D. (1R,9S)-Dxd is an ADC payload that can be used in the synthesis of ADCs (antibody-drug conjugates) .
    (1R,9S)-Dxd
  • HY-176415S
    Cys-MC-GGFG-Dxd-d5

    		Isotope-Labeled Compounds Drug-Linker Conjugates for ADC Cancer
    Cys-MC-GGFG-Dxd-d5 is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd can be used in cancer research .
    Cys-MC-GGFG-Dxd-d5
  • HY-168285
    LE01

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    LE01 is a drug-linker conjugate for ADC. LE01 contains a ADC linker and a DNA topoisomerase I inhibitor DXd (HY-13631D). LE01 can be used to synthesize HER2-targeting ADC (HER2-LE01) .
    LE01
  • HY-128979B
    Deruxtecan analog 2 monoTFA

    		Drug-Linker Conjugates for ADC Cancer
    Deruxtecan analog 2 (monoTFA) is a homolog of Deruxtecan (HY-13631E), a conjugate of the ADC toxin DX-8951 derivative (Dxd) with an ADC Linker .
    Deruxtecan analog 2 monoTFA
  • HY-W1124025
    (5-Cl)-DXd

    		ADC Payload Drug Derivative Cancer
    (5-Cl)-DXd, a derivative of DXd (HY-13631), is a cytotoxic drug that can be used in synthesis of CDH3-targeting antibody-drug conjugates (ADCs) .
    (5-Cl)-DXd
  • HY-176415S1
    Cys-MC-GGFG-Dxd-d5 TFA

    Cys-MC-GGFG-Dxd-d5 TFA

    		 Isotope-Labeled Compounds Drug-Linker Conjugates for ADC Cancer
    Cys-MC-GGFG-Dxd-d5 TFA (Cys-MC-GGFG-Dxd-d5 TFA) is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd-d5 TFA is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd-d5 TFA is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd-d5 TFA can be used in cancer research .
    Cys-MC-GGFG-Dxd-d5 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: